食品与药品
食品與藥品
식품여약품
FOOD AND DRUG
2015年
1期
55-58
,共4页
乳腺癌%辅助内分泌治疗%用药频率%用药趋势
乳腺癌%輔助內分泌治療%用藥頻率%用藥趨勢
유선암%보조내분비치료%용약빈솔%용약추세
breast cancer%adjuvant endocrine therapy%defined daily dose%trend of drug use
目的：调查乳腺癌内分泌治疗药物的临床应用情况及使用趋势，评价用药合理性。方法（1）分析山东大学附属省立医院2007~2010年乳腺癌内分泌治疗药物的销售金额、用药频率（DDD）及日用药金额（DDC）等指标。结果（1）2007~2010年乳腺癌内分泌治疗药物临床用药金额平均增长率60%以上，其中第3代芳香化酶抑制剂增长最快；DDD由高至低排序依次为他莫昔芬、来曲唑、依西美坦、阿那曲唑、托瑞米芬；DDC由低至高依次为他莫昔芬、托瑞米芬、依西美坦、来曲唑、阿那曲唑。结论山东大学附属省立医院乳腺癌内分泌治疗药物使用量增长明显，用药趋势与指南推荐相符，表明内分泌治疗作为乳腺癌综合治疗手段之一日益得到临床重视，但在药物选择与使用时机上仍存在不合理之处。
目的：調查乳腺癌內分泌治療藥物的臨床應用情況及使用趨勢，評價用藥閤理性。方法（1）分析山東大學附屬省立醫院2007~2010年乳腺癌內分泌治療藥物的銷售金額、用藥頻率（DDD）及日用藥金額（DDC）等指標。結果（1）2007~2010年乳腺癌內分泌治療藥物臨床用藥金額平均增長率60%以上，其中第3代芳香化酶抑製劑增長最快；DDD由高至低排序依次為他莫昔芬、來麯唑、依西美坦、阿那麯唑、託瑞米芬；DDC由低至高依次為他莫昔芬、託瑞米芬、依西美坦、來麯唑、阿那麯唑。結論山東大學附屬省立醫院乳腺癌內分泌治療藥物使用量增長明顯，用藥趨勢與指南推薦相符，錶明內分泌治療作為乳腺癌綜閤治療手段之一日益得到臨床重視，但在藥物選擇與使用時機上仍存在不閤理之處。
목적：조사유선암내분비치료약물적림상응용정황급사용추세，평개용약합이성。방법（1）분석산동대학부속성립의원2007~2010년유선암내분비치료약물적소수금액、용약빈솔（DDD）급일용약금액（DDC）등지표。결과（1）2007~2010년유선암내분비치료약물림상용약금액평균증장솔60%이상，기중제3대방향화매억제제증장최쾌；DDD유고지저배서의차위타막석분、래곡서、의서미탄、아나곡서、탁서미분；DDC유저지고의차위타막석분、탁서미분、의서미탄、래곡서、아나곡서。결론산동대학부속성립의원유선암내분비치료약물사용량증장명현，용약추세여지남추천상부，표명내분비치료작위유선암종합치료수단지일일익득도림상중시，단재약물선택여사용시궤상잉존재불합리지처。
Objective To investigate the clinical application status quo and tendency of adjuvant endocrine therapeutic drugs for breast cancer patients in our hospital, in order to evaluate the rationality of medication. Methods The consumption sum, defined daily dose (DDD), daily drug cost (DDC) and other indicators of the endocrine therapeutic drugs for breast cancer patients in Provincial Hospital Affiliated to Shandong University were analyzed from 2007 to 2010. Results The average growth rate of total consumption sum of endocrine therapeutic drugs for breast cancer patients had been more than 60 % during the period of 2007-2010. Among them, the third-generation aromatase inhibitors grew the most rapidly. DDDs from high to low were tamoxifen, letrozole, exemestane, anastrozole, toremifene, and DDC from low to high were tamoxifen, toremifene, exemestane, letrozole, anastrozole. Conclusion The total use of endocrine therapeutic drugs for breast cancer increased greatly, which is consistent with the guidelines recommend. Endocrine therapy as one of the comprehensive treatments for breast cancer has held increasing clinical attention, but there is still something unreasonable existing in the drug selection and use opportunity.
